EKTA-B Elekta AB (publ)

STO · SE · Healthcare · Medical Devices · elekta.com

52.95SEK+2.62%Mkt Cap: 1.94B $P/E: —Today

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers linear machin…

Industry Peers

Medical Devices

Screen all

ABT

Abbott Laboratories Common Stock

$169.83BUSDP/E 31.6

MDT

Medtronic plc. Ordinary Shares

$110.49BUSDP/E 21.2

SYK

Stryker Corporation Common Stock

$105.65BUSDP/E 28.5

BSX

Boston Scientific Corporation Common Stock

$61.74BUSDP/E 17.2

Edwards Lifesciences Corporation Common Stock

$49.03BUSDP/E 50.7

SHL

Siemens Healthineers AG

$46.06BUSDP/E 19.2

DXCM

DexCom, Inc. - Common Stock

$32.21BUSDP/E 33.7

GEHC

GE HealthCare Technologies Inc. - Common Stock

$29.24BUSDP/E 14.8

PHG

Koninklijke Philips N.V. NY Registry Shares

$23.38BUSDP/E 18.5

PHIA

Koninklijke Philips N.V.

$22.58BUSDP/E 18.5

STE

STERIS plc (Ireland) Ordinary Shares

Zimmer Biomet Holdings, Inc. Common Stock

$16.84BUSDP/E 21.4

PEN

Penumbra, Inc. Common Stock

$12.51BUSDP/E 77.8

TXG

10x Genomics, Inc. - Common Stock

$12.18BUSD

SNN

Smith & Nephew SNATS, Inc. Common Stock

$11.06BUSDP/E 18.0

GMED

Globus Medical, Inc. Class A Common Stock

Bio-Rad Laboratories, Inc. Class A Common Stock

$9.88BUSDP/E 45.0

GKOS

Glaukos Corporation Common Stock

$9.66BUSD

Key Statistics

Company

Market Cap1.94B USD

Enterprise Value2.40B USD

Revenue (TTM)1.59B USD

Gross Profit597.73M USD

Net Income (TTM)-49.64M USD

Revenue/Share43.47 SEK

Last Price52.95 SEK

Fiscal Year EndApr 2026

MR QuarterJul 2026

Employees4.0K

CountrySE

SectorHealthcare

IndustryMedical Devices

ISINUS28617Y1010

Valuation

P/E (Trailing)—

P/E (Forward)10.64

PEG0.38

EV/EBITDA13.59

EV/Revenue1.51

P/S1.19

P/B2.71

EPS (TTM)-0.95

EPS (Forward)4.85

52W Range

41.8645% of range66.70

52W High66.70 SEK

52W Low41.86 SEK

Profitability

Gross Margin37.38%

Oper. Margin10.49%

EBITDA Margin11.10%

Profit Margin-3.10%

ROE-7.31%

ROA-1.93%

Growth

Revenue Growth-3.00%

Earnings Growth146.40%

Cash Flow & Leverage

Operating CF235.69M USD

CapEx (TTM)102.54M USD

FCF Margin9.82%

FCF Yield8.06%

Net Debt432.83M USD

Net Debt/EBITDA2.45

Balance Sheet

Debt/Equity1.03

Current Ratio0.86

Quick Ratio0.62

Book Value/Sh19.05 SEK

Cash/Share5.80 SEK

Dividends

Fwd Div Rate2.40 SEK

Trail. Div Rate2.40 SEK

Div. Yield4.65%

5Y Avg Yield3.05%

Payout Ratio315.79%

Ex-Div DateMar 4, 2027

Pay Date—

Splits

Last Split4:1

Split DateSep 12, 2012

Analyst Consensus

Rating3.1 (Hold)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)58.26 SEK

Upside (mean)+10.0%

Target Range41.00 SEK – 90.00 SEK

41.00+10.0% to mean90.00

# Analysts14

Ownership

Shares Out.367.10M

Float325.92M

Insiders1.93%

Institutions64.60%

Technical

SMA 5051.91 (+2.0%)

SMA 20054.36 (-2.6%)

Beta0.98

S&P 52W Chg14.58%

Avg Vol (30d)901.55K

Avg Vol (10d)1.11M

Technical Indicators

RSI (14)50.6

MACD0.5847

MACD Signal0.7155

MACD Hist.-0.1308

BB Upper55.87 SEK

BB Middle51.95 SEK

BB Lower48.03 SEK

BB Width15.10%

ATR (14)1.435 SEK

Vol Ratio (20d)0.82x